SCHOTT Pharma Increases Syringe Nest Capacity by 60%

Pharmaceutical manufacturers around the world are facing increased regulatory pressure to ensure the highest levels of cleanliness, sterility, and particle control. The use of pre-sterilized RTU containment solutions has helped to ease this burden, and pharmaceutical packaging manufacturers have been stepping up to offer practical solutions suitable for high-speed, large-scale drug production.

RTU containers are often supplied in a nest format, which supports automated filling on both small and large aseptic filling and capping machinery. These pre-sterilized components mitigate risk for the manufacturer and offer a reduction in processing costs.

Pharmaceutical packaging giant, SCHOTT Pharma, has developed a new nest design for their RTU SCHOTT TOPPAC® polymer syringe range. The new design maintains the same nest dimensions while holding 160 syringes, which is a staggering 60% increase over the standard nest.

The new design will allow pharma companies to increase their efficiency by as much as 67%, significantly reducing manufacturing costs and lowering carbon footprint by 17%. In addition to reducing direct costs, further savings are achieved by minimizing transportation requirements, storage space, and ready-to-use waste.

By collaborating with Bausch+Ströbel, SCHOTT has created an RTU syringe nest that is fully compatible with their high-speed filling lines, requiring only minor retrofit changes to existing lines.

Talk to our team today to discuss your requirements

Adelphi has been a proud agent, stockist, and distributor for SCHOTT Pharma since 1985.